Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Svrcek

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 20, 2022
Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR)D Basile, C Broudin, J F Emile, et al.
Oncogene|September 15, 2015
The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease developmentA-L Joly, A Deepti, A Seignez, et al.
Oncogene|June 3, 2016
The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease developmentA-L Joly, A Deepti, A Seignez, et al.
British Journal of Cancer|November 8, 2013
Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic studyT Aparicio, M Svrcek, A Zaanan, et al.
Oncogene|November 8, 2016
HSP110 promotes colorectal cancer growth through STAT3 activationK Berthenet, A'dem Bokhari, A Lagrange, et al.
European Journal of Cancer (Oxford, England : 1990)|October 23, 2017
Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiencyR Cohen, O Buhard, P Cervera, et al.
ESMO Open|April 30, 2021
Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancerA Guyot D'Asnières De Salins, G Tachon, R Cohen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 16, 2020
Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort studyF Pagès, T André, J Taieb, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 2, 2012
Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinomaJ B Bachet, R Maréchal, P Demetter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 22, 2021
Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance)<sup>☆</sup>R Cohen, Q Shi, J Meyers, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 20, 2022
Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR)D Basile, C Broudin, J F Emile, et al.
Oncogene|September 15, 2015
The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease developmentA-L Joly, A Deepti, A Seignez, et al.
Oncogene|June 3, 2016
The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease developmentA-L Joly, A Deepti, A Seignez, et al.
British Journal of Cancer|November 8, 2013
Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic studyT Aparicio, M Svrcek, A Zaanan, et al.
Oncogene|November 8, 2016
HSP110 promotes colorectal cancer growth through STAT3 activationK Berthenet, A'dem Bokhari, A Lagrange, et al.
European Journal of Cancer (Oxford, England : 1990)|October 23, 2017
Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiencyR Cohen, O Buhard, P Cervera, et al.
ESMO Open|April 30, 2021
Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancerA Guyot D'Asnières De Salins, G Tachon, R Cohen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 16, 2020
Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort studyF Pagès, T André, J Taieb, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 2, 2012
Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinomaJ B Bachet, R Maréchal, P Demetter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 22, 2021
Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance)<sup>☆</sup>R Cohen, Q Shi, J Meyers, et al.
Pageof 4